Medifast, Inc.
Medifast, Inc. MED Peers
See (MED) competitors and their performances in Stock Market.
Peer Comparison Table: Personal Products & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MED | $12.68 | +1.68% | 139.4M | -21.49 | -$0.59 | N/A |
| ROL | $57.78 | -0.10% | 28B | 58.36 | $0.99 | +1.12% |
| SCI | $79.24 | +1.29% | 11.3B | 21.89 | $3.62 | +1.55% |
| HRB | $58.26 | +0.88% | 7.8B | 14.46 | $4.03 | +2.57% |
| BFAM | $126.93 | +0.79% | 7.3B | 45.82 | $2.77 | N/A |
| FTDR | $57.94 | +1.74% | 4.3B | 18.87 | $3.07 | N/A |
| DSEY | $8.40 | +0.06% | 2.7B | -14.47 | -$0.58 | N/A |
| MCW | $6.57 | +2.34% | 2.1B | 27.38 | $0.24 | N/A |
| ROVR | $11.00 | +0.05% | 2B | 183.25 | $0.06 | N/A |
| CSV | $45.05 | +1.08% | 707M | 15.07 | $2.99 | +1.00% |
Stock Comparison
MED vs ROL Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, ROL has a market cap of 28B. Regarding current trading prices, MED is priced at $12.68, while ROL trades at $57.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas ROL's P/E ratio is 58.36. In terms of profitability, MED's ROE is -0.03%, compared to ROL's ROE of +0.36%. Regarding short-term risk, MED is more volatile compared to ROL. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs SCI Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, SCI has a market cap of 11.3B. Regarding current trading prices, MED is priced at $12.68, while SCI trades at $79.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas SCI's P/E ratio is 21.89. In terms of profitability, MED's ROE is -0.03%, compared to SCI's ROE of +0.33%. Regarding short-term risk, MED is more volatile compared to SCI. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs HRB Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, HRB has a market cap of 7.8B. Regarding current trading prices, MED is priced at $12.68, while HRB trades at $58.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas HRB's P/E ratio is 14.46. In terms of profitability, MED's ROE is -0.03%, compared to HRB's ROE of -1.68%. Regarding short-term risk, MED is more volatile compared to HRB. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs BFAM Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, BFAM has a market cap of 7.3B. Regarding current trading prices, MED is priced at $12.68, while BFAM trades at $126.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas BFAM's P/E ratio is 45.82. In terms of profitability, MED's ROE is -0.03%, compared to BFAM's ROE of +0.12%. Regarding short-term risk, MED is more volatile compared to BFAM. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs FTDR Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, FTDR has a market cap of 4.3B. Regarding current trading prices, MED is priced at $12.68, while FTDR trades at $57.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas FTDR's P/E ratio is 18.87. In terms of profitability, MED's ROE is -0.03%, compared to FTDR's ROE of +1.04%. Regarding short-term risk, MED is less volatile compared to FTDR. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs DSEY Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, DSEY has a market cap of 2.7B. Regarding current trading prices, MED is priced at $12.68, while DSEY trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas DSEY's P/E ratio is -14.47. In terms of profitability, MED's ROE is -0.03%, compared to DSEY's ROE of -0.23%. Regarding short-term risk, MED is more volatile compared to DSEY. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs MCW Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, MCW has a market cap of 2.1B. Regarding current trading prices, MED is priced at $12.68, while MCW trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas MCW's P/E ratio is 27.38. In terms of profitability, MED's ROE is -0.03%, compared to MCW's ROE of +0.08%. Regarding short-term risk, MED is less volatile compared to MCW. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs ROVR Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, ROVR has a market cap of 2B. Regarding current trading prices, MED is priced at $12.68, while ROVR trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas ROVR's P/E ratio is 183.25. In terms of profitability, MED's ROE is -0.03%, compared to ROVR's ROE of -0.07%. Regarding short-term risk, MED is more volatile compared to ROVR. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs CSV Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, CSV has a market cap of 707M. Regarding current trading prices, MED is priced at $12.68, while CSV trades at $45.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas CSV's P/E ratio is 15.07. In terms of profitability, MED's ROE is -0.03%, compared to CSV's ROE of +0.23%. Regarding short-term risk, MED is more volatile compared to CSV. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs EM Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, EM has a market cap of 138.2M. Regarding current trading prices, MED is priced at $12.68, while EM trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas EM's P/E ratio is -109.00. In terms of profitability, MED's ROE is -0.03%, compared to EM's ROE of -0.01%. Regarding short-term risk, MED is more volatile compared to EM. This indicates potentially higher risk in terms of short-term price fluctuations for MED.
MED vs RGS Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, RGS has a market cap of 56.2M. Regarding current trading prices, MED is priced at $12.68, while RGS trades at $23.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas RGS's P/E ratio is 0.61. In terms of profitability, MED's ROE is -0.03%, compared to RGS's ROE of +1.58%. Regarding short-term risk, MED is less volatile compared to RGS. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs XSPA Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, XSPA has a market cap of 54.5M. Regarding current trading prices, MED is priced at $12.68, while XSPA trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas XSPA's P/E ratio is 21.83. In terms of profitability, MED's ROE is -0.03%, compared to XSPA's ROE of -1.20%. Regarding short-term risk, MED is less volatile compared to XSPA. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs YYGH Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, YYGH has a market cap of 52.2M. Regarding current trading prices, MED is priced at $12.68, while YYGH trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas YYGH's P/E ratio is -9.75. In terms of profitability, MED's ROE is -0.03%, compared to YYGH's ROE of -0.78%. Regarding short-term risk, MED is less volatile compared to YYGH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs WW Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, WW has a market cap of 20M. Regarding current trading prices, MED is priced at $12.68, while WW trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas WW's P/E ratio is -0.29. In terms of profitability, MED's ROE is -0.03%, compared to WW's ROE of +0.06%. Regarding short-term risk, MED is less volatile compared to WW. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs MRM Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, MRM has a market cap of 12.6M. Regarding current trading prices, MED is priced at $12.68, while MRM trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas MRM's P/E ratio is 7.98. In terms of profitability, MED's ROE is -0.03%, compared to MRM's ROE of -0.39%. Regarding short-term risk, MED is less volatile compared to MRM. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs EJH Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, EJH has a market cap of 10.1M. Regarding current trading prices, MED is priced at $12.68, while EJH trades at $2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas EJH's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.03%, compared to EJH's ROE of -0.15%. Regarding short-term risk, MED is less volatile compared to EJH. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs IVP Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, IVP has a market cap of 8.8M. Regarding current trading prices, MED is priced at $12.68, while IVP trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas IVP's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.03%, compared to IVP's ROE of -11.83%. Regarding short-term risk, MED is less volatile compared to IVP. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs TRNR Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, TRNR has a market cap of 8.8M. Regarding current trading prices, MED is priced at $12.68, while TRNR trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas TRNR's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.03%, compared to TRNR's ROE of -13.46%. Regarding short-term risk, MED is less volatile compared to TRNR. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs XWEL Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, XWEL has a market cap of 5.1M. Regarding current trading prices, MED is priced at $12.68, while XWEL trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas XWEL's P/E ratio is -0.23. In terms of profitability, MED's ROE is -0.03%, compared to XWEL's ROE of -2.71%. Regarding short-term risk, MED is less volatile compared to XWEL. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs NEBCU Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, NEBCU has a market cap of 0. Regarding current trading prices, MED is priced at $12.68, while NEBCU trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas NEBCU's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.03%, compared to NEBCU's ROE of -0.07%. Regarding short-term risk, MED is less volatile compared to NEBCU. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs TMX Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, TMX has a market cap of 0. Regarding current trading prices, MED is priced at $12.68, while TMX trades at $37.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas TMX's P/E ratio is 70.13. In terms of profitability, MED's ROE is -0.03%, compared to TMX's ROE of +0.05%. Regarding short-term risk, MED is less volatile compared to TMX. This indicates potentially lower risk in terms of short-term price fluctuations for MED.
MED vs STON Comparison
MED plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MED stands at 139.4M. In comparison, STON has a market cap of 0. Regarding current trading prices, MED is priced at $12.68, while STON trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MED currently has a P/E ratio of -21.49, whereas STON's P/E ratio is -6.64. In terms of profitability, MED's ROE is -0.03%, compared to STON's ROE of +0.48%. Regarding short-term risk, MED is more volatile compared to STON. This indicates potentially higher risk in terms of short-term price fluctuations for MED.